Kieran Murray1,2, Matthew Turk3,4, Yousef Alammari3,4, Francis Young3,4, Phil Gallagher3,4, Tajvur Saber5, Ursula Fearon6, Douglas J Veale3,4. 1. Department of Rheumatology, St Vincent's University Hospital, Dublin 4, Ireland. kemurray@hotmail.com. 2. EULAR Centre for Arthritis and Rheumatic Diseases, Dublin, Ireland. kemurray@hotmail.com. 3. Department of Rheumatology, St Vincent's University Hospital, Dublin 4, Ireland. 4. EULAR Centre for Arthritis and Rheumatic Diseases, Dublin, Ireland. 5. Lady Reading Hospital, Soekarno Rd, PTCL Colony Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan. 6. Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, D06 R590, Ireland.
Abstract
BACKGROUND: Biologic therapies have greatly improved outcomes in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Yet, our ability to predict long-term remission and persistence or continuation of therapy remains limited. This study explores predictors of remission and persistence of the initial biologic therapy in patients after 12 years. Furthermore, outcomes with adalimumab and etanercept are compared. PATIENTS AND METHODS: RA and PsA patients were prospectively recruited from a biologic clinic. Outcomes on commencing therapy, at 1 year and 12 years were reviewed. Demographics, medications, morning stiffness, patient global health score, tender and swollen joint counts, antibody status, CRP and HAQ were collected. Outcomes at 1 year and 12 years are reported and predictors of biologic persistence and EULAR-defined remission (DAS28-CRP < 2.6) are examined with univariate and multivariate analysis. RESULTS: A total of 403 patients (274 RA and 129 PsA) were analysed. PsA patients were more likely to be male, in full-time employment and have completed higher education. PsA had higher remission rates than RA at both 1 year (60.3% versus 34.5%, p < 0.001) and 12 years (91.3% versus 60.6%, p < 0.001). This difference persisted when patients were matched for baseline disease activity (p < 0.001). Biologic continuation rates were high for RA and PsA at 1 year (49.6% versus 58.9%) and 12 years (38.2% versus 52.3%). In PsA, patients starting on etanercept had lower CRP at 12 years (p = 0.041). Multivariate analysis showed 1-year continuation [OR 4.28 (1.28-14.38)] and 1-year low-disease activity [OR 3.90 (95% CI 1.05-14.53)] was predictive of a 12-year persistence. Persistence with initial biologic at 12 years [OR 4.98 (95% CI 1.83-13.56)] and male gender [OR 4.48 (95% CI 1.25-16.01)] predicted 12 year remission. CONCLUSIONS: This is the first study to show better response to biologic therapy in PsA compared to RA at 12 years. Long-term persistence with initial biologic agent was high and was predicted by biologic persistence and low-disease activity at 1 year. Interestingly, PsA patients had higher levels of employment, educational attainment, and long-term remission rates compared to RA patients.
BACKGROUND: Biologic therapies have greatly improved outcomes in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Yet, our ability to predict long-term remission and persistence or continuation of therapy remains limited. This study explores predictors of remission and persistence of the initial biologic therapy in patients after 12 years. Furthermore, outcomes with adalimumab and etanercept are compared. PATIENTS AND METHODS: RA and PsA patients were prospectively recruited from a biologic clinic. Outcomes on commencing therapy, at 1 year and 12 years were reviewed. Demographics, medications, morning stiffness, patient global health score, tender and swollen joint counts, antibody status, CRP and HAQ were collected. Outcomes at 1 year and 12 years are reported and predictors of biologic persistence and EULAR-defined remission (DAS28-CRP < 2.6) are examined with univariate and multivariate analysis. RESULTS: A total of 403 patients (274 RA and 129 PsA) were analysed. PsA patients were more likely to be male, in full-time employment and have completed higher education. PsA had higher remission rates than RA at both 1 year (60.3% versus 34.5%, p < 0.001) and 12 years (91.3% versus 60.6%, p < 0.001). This difference persisted when patients were matched for baseline disease activity (p < 0.001). Biologic continuation rates were high for RA and PsA at 1 year (49.6% versus 58.9%) and 12 years (38.2% versus 52.3%). In PsA, patients starting on etanercept had lower CRP at 12 years (p = 0.041). Multivariate analysis showed 1-year continuation [OR 4.28 (1.28-14.38)] and 1-year low-disease activity [OR 3.90 (95% CI 1.05-14.53)] was predictive of a 12-year persistence. Persistence with initial biologic at 12 years [OR 4.98 (95% CI 1.83-13.56)] and male gender [OR 4.48 (95% CI 1.25-16.01)] predicted 12 year remission. CONCLUSIONS: This is the first study to show better response to biologic therapy in PsA compared to RA at 12 years. Long-term persistence with initial biologic agent was high and was predicted by biologic persistence and low-disease activity at 1 year. Interestingly, PsA patients had higher levels of employment, educational attainment, and long-term remission rates compared to RApatients.
Authors: Ramon Lyu; Marinella Govoni; Qian Ding; Christopher M Black; Sumesh Kachroo; Tao Fan; Augstina Ogbonnaya; Prina Donga; Jerrold Hill; Charles Makin Journal: Rheumatol Int Date: 2015-08-28 Impact factor: 2.631
Authors: K P Machold; T A Stamm; V P K Nell; S Pflugbeil; D Aletaha; G Steiner; M Uffmann; J S Smolen Journal: Rheumatology (Oxford) Date: 2006-08-09 Impact factor: 7.580
Authors: Maurizio Cutolo; Alberto Sulli; Silvia Capellino; Barbara Villaggio; Paola Montagna; Carmen Pizzorni; Sabrina Paolino; Bruno Seriolo; Lamberto Felli; Rainer H Straub Journal: Ann N Y Acad Sci Date: 2006-06 Impact factor: 5.691
Authors: Joel M Gelfand; Dafna D Gladman; Philip J Mease; Nana Smith; David J Margolis; Tamar Nijsten; Robert S Stern; Steven R Feldman; Tara Rolstad Journal: J Am Acad Dermatol Date: 2005-10 Impact factor: 11.527
Authors: Achilleas Floudas; Aine Gorman; Nuno Neto; Michael G Monaghan; Zoe Elliott; Ursula Fearon; Viviana Marzaioli Journal: Front Med (Lausanne) Date: 2022-03-14
Authors: Ronaldo José Faria; Francisca Janiclecia Rezende Cordeiro; Jéssica Barreto Ribeiro Dos Santos; Juliana Alvares-Teodoro; Augusto Afonso Guerra Júnior; Francisco de Assis Acurcio; Michael Ruberson Ribeiro da Silva Journal: Front Pharmacol Date: 2022-04-26 Impact factor: 5.988
Authors: Laure Gossec; Stefan Siebert; Paul Bergmans; Kurt de Vlam; Elisa Gremese; Beatríz Joven-Ibáñez; Tatiana V Korotaeva; Frederic Lavie; Wim Noël; Michael T Nurmohamed; Petros P Sfikakis; Elke Theander; Josef S Smolen Journal: Ann Rheum Dis Date: 2022-02-24 Impact factor: 27.973
Authors: Iain B McInnes; Proton Rahman; Alice B Gottlieb; Elizabeth C Hsia; Alexa P Kollmeier; Xie L Xu; Yusang Jiang; Shihong Sheng; May Shawi; Soumya D Chakravarty; Désirée van der Heijde; Philip J Mease Journal: Arthritis Rheumatol Date: 2022-02-07 Impact factor: 15.483